«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2021 04

Page:

616-620

Research Field:

Publishing date:

Info

Title:

Efficacy and safety of trastuzumab with FLOT regimen in perioperative treatment of resectable HER-2+ advanced gastric cancer

Author(s):

TONG Gangling¹; CHENG Boran¹; WU Xuan¹; HE Lirui²; WANG Li¹; LYU Guoqing²; WANG Shubin¹

1.Department of Oncology£¬Peking University Shenzhen Hospital,Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research,Cancer Institute of Shenzhen-PKU-HKUST Medical Center,Guangdong Shenzhen 518036,China;2.Gastrointestinal Surgery,Peking

Keywords:

gastric cancer; HER-2; perioperative chemotherapy; trastuzumab

PACS:

R735.2

DOI:

10.3969/j.issn.1672-4992.2021.04.015

Abstract:

Objective£ºTo test efficacy and safety of the perioperative FLOT regimen given in combination with trastuzumab(T) in patients with resectable human epidermal growth factor receptor-2 positive(HER-2+) advanced GC.Methods:FLOT regimen consisting of docetaxel(50 mg/m2),oxaliplatin(85 mg/m2),leucovorin(200 mg/m2),and 5-FU (2 600 mg/m2 as a 24 h infusion),all given on day 1 and administered every 2 weeks,for 4 cycles of 3 weeks before and after surgery,plus T(8 mg/kg loading dose,followed by 6 mg/kg every 3 weeks) on day 1,22 and 43,independent of the chemotherapy regimen chosen,for 3 cycles of 3 weeks before and after surgery.The objective response rate (ORR),disease control rate(DCR),tumor regression grade(TRG),safety and overall survival(OS) were observed.Results:Thirty-one patients were included in this retrospective study.Median follow-up of patients was 24.5 months.After the therapy,the patients of complete response(CR),partial response(PR),stable response£¨SD£© and progression disease£¨PD£© were 5(16.1%),18(58.1%),5(16.1%) and 3(9.7%).The ORR was 74.2%£¨23/31£©,and DCR was 90.3%£¨28/31£©.R0 resection was obtained in 30(96.8%) patients.Five patients (16.1%) had TRG1a and 8(25.8%) patients had TRG1b.No relapse was observed in patients with TRG1a/b.The most common grade 3-4 adverse events were neutropenia£¨19.4%£© and vomiting (3.23%).The 2-year OS was 78.6%.Conclusion:Trastuzumab combined with FLOT regimen could be efficient and safely administrated in perioperative treatment of resectable HER-2+ advanced GC.

References:

£Û1£ÝSYMEONIDIS D,DIAMANTIS A,E MAGOULIOTIS D,et al.Lymph node harvesting in gastric cancer:The crucial role of T stage£ÛJ£Ý.J BUON,2020,25(1):319-323.
£Û2£ÝJAYANATHAN M,ERWIN RP,MOLACEK N,et al.MAGIC versus MacDonald treatment regimens for gastric cancer:Trends and predictors of multimodal therapy for gastric cancer using the national cancer database£ÛJ£Ý.Am J Surg,2020,219(1):129-135.
£Û3£ÝZAANAN A,BOUCH¦I O,BENHAIM L,et al.Gastric cancer:French intergroup clinical practice guidelines for diagnosis,treatments and follow-up (SNFGE,FFCD,GERCOR,UNICANCER,SFCD,SFED,SFRO)£ÛJ£Ý.Dig Liver Dis,2018,50(8):768-779.
£Û4£ÝESAKIA T,METONIDZE B,TURKIASHVILI L,et al.Perioperative chemotherapy with FLOT vs other regimens for resectable gastric cancer£ÛJ£Ý.Ann Oncol,2019,30£¨Suppl 4£©:iv60.
£Û5£ÝPEREIRA MA,RAMOS MFKP,DIAS AR,et al.Expression profile of markers for targeted therapy in gastric cancer patients:HER-2,microsatellite instability and PD-L1£ÛJ£Ý.Mol Diagn Ther,2019,23(6):761-771.
£Û6£ÝCHEN J,YE Q,HUANG F.Historical evolution and research progress of perioperative therapy of locally advanced gastric cancer£ÛJ£Ý.Chin J Gastrointest Surg,2019,22(2):196-200.
£Û7£ÝROVIELLO G,ROVIELLO F,MINI E£¬et al.Perioperative chemotherapy for gastric cancer in FLOT4£ÛJ£Ý.Lancet,2020,395(10218):e3.
£Û8£ÝTABERNERO J,HOFF PM,SHEN L.Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB):final analysis of a double-blind,randomised,placebo-controlled phase 3 study£ÛJ£Ý.Lancet Oncol,2018,19(10):1372-1384.
£Û9£ÝWANG K,REN Y,MA Z,et al.Docetaxel,oxaliplatin,leucovorin,and 5-fluorouracil (FLOT) as preoperative and postoperative chemotherapy compared with surgery followed by chemotherapy for patients with locally advanced gastric cancer:A propensity score-based analysis£ÛJ£Ý.Cancer Manag Res,2019,11:3009-3020.
£Û10£ÝTANAKA Y,KUNISAKI C,IZUMISAWA Y,et al.A phase I/II study of NAC with docetaxel,cisplatin,and S-1 for stage III gastric cancer£ÛJ£Ý.Anticancer Res,2018,38(10):6015-6021.
£Û11£ÝWAGNER AD,GRABSCH HI,MAUER M,et al.EORTC-1203-GITCG-The "INNOVATION"-trial:Effect of chemotherapy alone versus chemotherapy plus trastuzumab,versus chemotherapy plus trastuzumab plus pertuzumab,in the perioperative treatment of HER2 positive,gastric and gastroesophageal junction adenocarcinoma on pathologic response rate:A randomized phase II-intergroup trial of the EORTC-gastrointestinal tract cancer group,Korean cancer study group and Dutch upper GI-cancer group£ÛJ£Ý.BMC Cancer,2019,19(1):494.
£Û12£ÝRIVERA F,ROMERO C,JIMENEZ-FONSECA P,et al.Phase II study to evaluate the efficacy of trastuzumab in combination with capecitabine and oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer:HERXO trial£ÛJ£Ý.Cancer Chemother Pharmacol,2019,83(6):1175-1181.
£Û13£ÝSCHULZ C,KULLMANN F,KUNZMANN V,et al.NeoFLOT:Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors£ÛJ£Ý.Int J Cancer,2015,137(3):678-685.
£Û14£ÝAl-BATRAN SE,HOFHEINZ RD,PAULIGK C,et al.Histopathological regression after neoadjuvant docetaxel,oxaliplatin,fluorouracil,and leucovorin versus epirubicin,cisplatin,and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO):results from the phase 2 part of a multicentre,open-label,randomised phase 2/3 trial£ÛJ£Ý.Lancet Oncol,2016,17(12):1697-1708.
£Û15£ÝKANO M,HAYANO K,HAYASHI H,et al.Survival benefit of neoadjuvant chemotherapy with S-1 plus docetaxel for locally advanced gastric cancer:A propensity score-matched analysis£ÛJ£Ý.Ann Surg Oncol,2019,26(6):1805-1813.
£Û16£ÝCUNNINGHAM D,STENNING SP,SMYTH EC,et al.Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03):primary analysis results of a multicentre,open-label,randomised phase 2-3 trial£ÛJ£Ý.Lancet Oncol,2017,18(3):357-370.
£Û17£ÝADENIS A,SAMALIN E,MAZARD T,et al.Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer£ÛJ£Ý.Bull Cancer,2020,107(1):54-60.

Memo

Memo:

¹ã¶«Ê¡×ÔÈ»¿Æѧ»ù½ð£¨±àºÅ£º2018A0303100026£©£»ÉîÛÚÊпƼ¼´´ÐÂίԱ»á»ù½ð£¨±àºÅ£ºGJHZ20180420180754917, ZDSYS20190902092855097£¬JCYJ20190809100005672£©£»ÉîÛÚÊÐÈýÃû¹¤³ÌÏîÄ¿£¨±àºÅ£ºSZSM201612041£©

Common functions

Last Update: 1900-01-01